Key Highlights

  • Artrya (ASX:AYA) was trading at A$4.92 at the time of writing on 14 August 2026, up A$0.229 or 4.904% on the day.
  • Tanner Health is using Salix® routinely across five hospitals, while Northeast Georgia Health System became Artrya’s second revenue-generating US customer in July.
  • Validation of Salix® Coronary Flow has progressed toward a US FDA 510(k) submission, with clearance and commercial launch targeted for the second half of calendar 2026.
  • Artrya held A$74.0 million in cash and term deposits at 30 June 2026, including a A$30 million six-month bank term deposit.

Artrya (ASX:AYA) was trading at A$4.92 at the time of writing on 14 August 2026, up A$0.229, or 4.904%, on the day. The company’s quarterly activities and Cash Flow update released on 29 July 2026, outlined progress in US customer deployments, development of the Salix® platform, regulatory preparations and the company’s cash position during the June 2026 quarter.

Artrya is developing and commercialising Salix®, an artificial intelligence-powered cloud platform designed to support the assessment and management of coronary artery disease. During the June quarter, the company continued moving from initial customer implementation towards broader clinical use across its US health system relationships.

Tanner Health continues routine clinical use

Tanner Health remains Artrya’s most advanced US customer. Salix® Coronary Anatomy and Salix® Coronary Plaque are fully operational across all five Tanner Health hospitals and are being used in routine clinical practice.

The company reported that scan volumes and fee-per-scan Revenue are increasing at the customer. Artrya is also working with Tanner Health on reimbursement processes and pre-authorisation workflows. These initiatives are intended to support the use of Salix® and provide an implementation framework that can be applied as additional US health systems are deployed.

Northeast Georgia Health System became Artrya’s second revenue-generating customer after the deployment of Salix® Coronary Anatomy was completed in July. The company plans to expand Salix® across the wider hospital network, with utilisation and scan volumes forming part of the next stage of implementation.

At Cone Health, Artrya’s customer success team continues to work with cardiology and information technology teams on integration activities ahead of clinical deployment. The company has stated an objective of having all three foundation customers generating revenue from Salix® Coronary Anatomy and Plaque by the end of the September quarter.

Coronary Flow progresses toward FDA submission

Another significant development during the quarter was progress on Salix® Coronary Flow. Artrya completed validation and pre-submission activities and secured the required US clinical datasets for the regulatory process.

Salix® Coronary Flow is designed to provide near real-time, non-invasive coronary blood-flow assessment from standard CT scans. The module generates Fractional Flow Reserve measurements intended to assist clinicians in assessing coronary artery disease and identifying patients who may be able to avoid unnecessary invasive angiography.

Artrya is targeting submission of the module to the US Food and Drug Administration and has set a target of FDA clearance and commercial launch during the second half of calendar 2026. The company also stated that Coronary Flow assessments would be eligible for reimbursement under an existing Category I CPT code, currently reimbursed at US$877 per scan.

SAPPHIRE study builds clinical and commercial pipeline

Artrya has also commenced its SAPPHIRE Study, with investigators from participating US health systems meeting in San Diego in July. Protocol reviews, contracting and ethics processes are progressing, followed by planned retrospective data collection.

The study is focused on Salix® Coronary Plaque and the company’s Plaque Dispersion Score, assessing their potential role in coronary artery disease identification, risk stratification and management. Participating health systems are also gaining experience with the platform, creating a pathway from clinical research activity to potential commercial relationships.

The company is further establishing a Clinical Advisory Board, chaired by Dr Ron Blankstein of Mass General Brigham and Harvard Medical School. The board is intended to provide input across clinical practice, product development, evidence generation and adoption.

Cash position provides funding visibility

Artrya reported A$74.0 million in cash and term deposits at 30 June 2026. This included A$44.0 million of cash and cash equivalents and a A$30.0 million six-month bank term deposit classified separately as a financial asset.

Net operating cash outflows for the quarter were A$4.75 million, while the company received A$1.2 million in interest income and A$0.5 million in Research and Development rebate payments. Financing activities generated A$2.3 million from the exercise of options.

The Quarterly Report recorded customer receipts of A$0.06 million, reflecting subscription and per-scan revenue from Tanner Health. Operating costs, excluding interest income and the R&D rebate, were A$6.4 million, compared with A$6.8 million in the preceding quarter.

Conclusion

Artrya’s June quarter update describes a Business progressing across commercial deployment, regulatory preparation and clinical evidence generation in the US market. Tanner Health has moved into routine use, Northeast Georgia Health System has become a second revenue-generating customer and Cone Health is progressing towards deployment. At the same time, Salix® Coronary Flow has advanced toward its FDA submission, while the SAPPHIRE Study is establishing another channel for clinical evidence and potential commercial relationships. The A$74.0 million cash and term-deposit position at 30 June 2026 provides the financial backdrop as Artrya works toward broader customer adoption and its targeted second-half calendar 2026 regulatory and commercial milestones.